Pfizer stock hits 52-week low at $24.42 amid market shifts

Pfizer Inc. (NYSE:PFE) shares have touched a 52-week low, dipping to $24.42, as investors navigate a complex healthcare market landscape. According to InvestingPro analysis, the pharmaceutical giant appears undervalued at current levels, with a market capitalization of $139 billion and notably low price volatility (Beta: 0.54). The pharmaceutical giant, known for its broad portfolio of medicines and vaccines, has seen its stock price fluctuate over the past year, culminating in this recent low point. Despite the challenges faced by the industry, including pricing pressures and a competitive drug market, Pfizer’s stock has demonstrated resilience in the past. The company maintains a robust 7.01% dividend yield and generates substantial revenue of $63.6 billion. With an overall Financial Health Score of "GOOD" from InvestingPro, which offers 8 additional exclusive insights about PFE’s potential, the company continues to focus on strategic initiatives and research developments, aiming to revitalize its stock performance in the upcoming quarters.

In other recent news, Bernstein released a report highlighting tariff risks within the biopharma sector, identifying Merck (NSE:PROR) & Co. and AbbVie (NYSE:ABBV) as among the most exposed due to significant imports and external manufacturing reliance. The analysis suggests these companies may face increased costs from tariff adjustments, while Eli Lilly (NYSE:LLY), Gilead Sciences (NASDAQ:GILD), Bristol Myers (NYSE:BMY) Squibb, and Moderna (NASDAQ:MRNA) are deemed to have moderate exposure. Meanwhile, Moderna faces uncertainty following the resignation of Dr. Peter Marks from the FDA, which could impact its vaccine business. Truist analyst Joon Lee commented on potential volatility for companies like Moderna due to this leadership change. Additionally, several European drugmakers are reportedly expediting shipments to the U.S. to preempt potential tariff disruptions, reflecting industry concerns over trade policies.

Pfizer has been the subject of analyst reviews, with Berenberg maintaining a Hold rating and a $28 price target, emphasizing the importance of pipeline execution amid patent expiration challenges. The company’s recent acquisition of Seagen aims to bolster long-term sales growth, though some assets have been marked down. Citi analyst Geoff Meacham also maintained a Neutral rating and a $27 price target on Pfizer, amid an investigation into the timing of its COVID-19 vaccine announcement. Despite the probe, Citi suggests the long-term impact on Pfizer is expected to be minimal, with more significant concerns surrounding policy changes and exclusivity losses.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.